Do GNOM and PBE hold the same stocks?

By their latest filings, 30% of their books are the same securities at the same weight. Overlap is the sum of the smaller weight of every security they share.

Which is more different from the S&P 500, GNOM or PBE?

GNOM has 21% of its weight in S&P 500 names and PBE has 32%, so PBE differs more from the index.

Which is cheaper, GNOM or PBE?

GNOM charges 0.50% a year and PBE charges 0.59%, so GNOM is cheaper. Fees come from each fund's prospectus.

Data as of Nov 4, 2026.

Thematic ETFs

GNOM vs PBE: Holdings Overlap & Returns

Share on X Download as PDF

Over the year to Nov 4, 2026, GNOM returned +66.6% to PBE's +44.2%; 30% of their weight is in the same names.

askIQ about this page

askIQ about GNOM and PBE

Net assets: $104m on Oct 12, 2026 for Global X Genomics & Biotechnology ETF, and $442m on Nov 3, 2026 for Invesco Biotechnology & Genome ETF.

GNOM on its own →PBE on its own →

At a glance

21.0%

GNOM in the S&P 500

32.3%

PBE in the S&P 500

+66.6%

GNOM total return, 1 year

+44.2%

PBE total return, 1 year

GNOM · 1 year to Nov 4, 2026 79% of its weight is outside the S&P 500

21% of GNOM's weight is in S&P 500 companies and 79% is outside the index. Holdings as of Aug 31, 2026.

PBE · 1 year to Nov 4, 2026 68% of its weight is outside the S&P 500

32% of PBE's weight is in S&P 500 companies and 68% is outside the index. Holdings as of Nov 3, 2026.

Pair scorecard

GNOM costs 0.09 points a year less; their one-year returns differ by 22.4 points; PBE is 4.0 times larger.

GNOM vs PBE: Holdings Overlap & Returns
Measure	GNOM	PBE
Return
Measure	GNOM	PBE
Total return, 1 year	+66.6%	+44.2%
Drawdown
Measure	GNOM	PBE
Below its all-time high	36.2%, high on Feb 8, 2021
Benchmark
Measure	GNOM	PBE
What it tracks	Genomics and gene editing	Biotech
Cost and size
Measure	GNOM	PBE
Expense ratio	0.50%	0.59%
Net assets, as of Oct 12, 2026	$104m	$419m
Holdings
Measure	GNOM	PBE
Holdings in common	30%

Method

Risk and return

Apr 18, 2019 to Oct 30, 2026 · 393 weekly returns

GNOM PBE

Return

Total return edge PBE +25.4% +102.7%

Annualized edge PBE +3.0% +9.8%

Price return edge PBE +23.4% +98.0%

Risk

Volatility edge PBE 32.9% 23.7%

Max drawdown edge PBE −73.5% −35.9%

Risk-adjusted

Sharpe edge PBE 0.17 0.39

Sortino edge PBE 0.25 0.58

Calmar edge PBE 0.04 0.27

Reading

From Apr 2019 to Oct 2026, PBE returned more: +102.7% to +25.4%. PBE swung less: 23.7% to 32.9%. PBE fell less at its worst: −35.9% to −73.5%.

Full scorecard

9 measures, with how each is measured Open ↓

Risk and return: GNOM vs PBE: Holdings Overlap & Returns
Measure	GNOM	PBE	Edge	How it is measured
Return
Total return	+25.4%	+102.7%	PBE	Price change plus distributions, reinvested.
Annualized	+3.0%	+9.8%	PBE	Total return as a yearly rate.
Price return	+23.4%	+98.0%	PBE	Price change alone, distributions left out.
Risk
Volatility	32.9%	23.7%	PBE	Spread of weekly returns, annualized. Lower is steadier.
Downside deviation	22.3%	15.9%	PBE	Like volatility, counting only weeks below the Treasury bill rate.
Max drawdown	−73.5%	−35.9%	PBE	Deepest fall from a high to the low after it.
Risk-adjusted
Sharpe	0.17	0.39	PBE	Return above Treasury bills per unit of volatility.
Sortino	0.25	0.58	PBE	Return above Treasury bills per unit of downside deviation.
Calmar	0.04	0.27	PBE	Annualized return divided by the max drawdown.

Computed by ETFIQ from Tiingo daily prices and ETFIQ's distribution records, 393 weekly returns. Cash rate: the 13-week Treasury bill.

What they share

30%

By the books each fund has filed, GNOM and PBE hold 30% of their money in the same securities at the same weight. Holdings dated Aug 31, 2026 and Nov 3, 2026.

50%

0 half 100%

half

30% in common

Positions both hold · largest shared weight first GNOM PBE

ILLUMINA, INC. 4.87% 5.10%

NATERA, INC. 4.61% 5.56%

MODERNA, INC. 7.50% 3.78%

VERTEX PHARMACEUTICALS INCORPORATED 3.70% 4.62%

Qiagen N.V. 3.22% 3.03%

Veracyte, Inc. 2.61% 3.00%

Legend Biotech Corporation 2.38% 2.65%

BIOMARIN PHARMACEUTICAL INC. 3.58% 2.21%

GILEAD SCIENCES, INC. 1.64% 5.42%

SAREPTA THERAPEUTICS, INC. 1.63% 2.57%

Only in one fund ↓

Only in GNOM

Twist Bioscience Corporation 6.34%

10x Genomics, Inc. 5.48%

GUARDANT HEALTH, INC. 5.28%

Genscript Biotech Corp 3.81%

BIO-TECHNE CORPORATION 3.67%

ARROWHEAD PHARMACEUTICALS, INC. 3.31%

Praxis Precision Medicines, Inc. 3.09%

CRISPR Therapeutics AG 3.00%

Only in PBE

Regeneron Pharmaceuticals Inc 5.62%

Biogen Inc 5.43%

Royalty Pharma PLC 5.15%

Amgen Inc 5.02%

Exelixis Inc 3.35%

Halozyme Therapeutics Inc 3.09%

United Therapeutics Corp 3.05%

TG Therapeutics Inc 2.88%

Check overlap with more funds →

Window by window

Window by window: GNOM vs PBE: Holdings Overlap & Returns
	Total return
Window	GNOM	PBE
3 months	+24.5%	+14.2%
6 months	+49.4%	+27.1%
1 year	+66.6%	+44.2%
3 years	+81.6%	+90.4%
Since launchNot the same days: GNOM Apr 2019 · PBE Jun 2005	+16.0%	+650.5%

Open this comparison in the app →

Side by side

GNOM Global X Genomics & Biotechnology ETF · Holds 50 stocks in genomics and gene editing, 21% of its weight in S&P 500 companies PBE Invesco Biotechnology & Genome ETF · Holds 32 stocks in biotech, 32% of its weight in S&P 500 companies

Issuer Global X Invesco

Theme Genomics and gene editing Biotech

In the S&P 500 21.0% 32.3%

Active share vs the S&P 500 97.6% 99.0%

In the Nasdaq-100 5.3% 20.7%

Holdings 50 32

Top ten, share of the fund 48.8% 49.1%

Expense ratio 0.50% 0.59%

Fee for the differing part 0.51% 0.60%

Total return, 1 year +66.6% +44.2%

vs its benchmark not measured not measured

Below its high −36.2% 0.0%

Net assets, GNOM as of Oct 12, 2026 and PBE as of Nov 3, 2026 $104m $442m

As of Nov 4, 2026. Source: ETFIQ.

30% of the two portfolios are the same securities at the same weight.

Client brief:

The two-page PDF for this pair is coming. Save the comparison to follow its changes. Free. It needs an email sign-in, once.

Your saved page · Privacy.

Alert

About each fund

GNOM

By weight, 21% of GNOM's portfolio is stocks that are also in the S&P 500; its active share against the S&P 500 is 98%. The top ten holdings are 49% of the fund across 50 positions, as filed for Aug 31, 2026. Over the year to Nov 4, 2026 the fund returned +66.6% with distributions reinvested. It sits 36.2% below its all-time high of Feb 8, 2021.

PBE

By weight, 32% of PBE's portfolio is stocks that are also in the S&P 500; its active share against the S&P 500 is 99%. The top ten holdings are 49% of the fund across 32 positions, as published by its issuer for Nov 3, 2026. Over the year to Nov 4, 2026 the fund returned +44.2% with distributions reinvested.

Questions people ask

Do GNOM and PBE hold the same stocks?: By their latest filings, 30% of their books are the same securities at the same weight. Overlap is the sum of the smaller weight of every security they share.
Which is more different from the S&P 500, GNOM or PBE?: GNOM has 21% of its weight in S&P 500 names and PBE has 32%, so PBE differs more from the index.
Which is cheaper, GNOM or PBE?: GNOM charges 0.50% a year and PBE charges 0.59%, so GNOM is cheaper. Fees come from each fund's prospectus.

Other comparisons

GNOM vs IBBQ GNOM vs FBT GNOM vs XBI GNOM vs IBB PBE vs IDNA PBE vs ARKG PBE vs GNMX PBE vs BBH

Where to next

All thematic ETFs ranked by the S&P 500 Difference Score →How the scores are computed →GNOM on its own →PBE on its own →GNOM dividend history →GNOM holdings →PBE dividend history →PBE holdings →Method →Standards and sources →

Sources and dates

GNOM filings on SEC EDGAR ↗

GNOM prospectus with the expense ratio (SEC) ↗

Global X page for GNOM ↗

PBE filings on SEC EDGAR ↗

PBE prospectus with the expense ratio (SEC) ↗

Invesco page for PBE ↗

Links are sources, not endorsements. A comparison is not a recommendation.

How this is computed

Overlap adds up the smaller of the two weights for each security both funds hold.

Every number is an ETFIQ calculation with distributions reinvested.

Cite this pageCitation, APA and Markdown

ETFIQ, GNOM against PBE, data as of Nov 4, 2026. https://etfiq.com/compare/themes/gnom-vs-pbe

Open data →

Free to use with attribution for data ETFIQ computes; issuer data stays under its owner's terms.